Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent in accordance with federal, local, and institutional guidelines~* Patients with metastatic pancreatic adenocarcinoma not treated with chemotherapy for metastatic disease~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Absolute neutrophil count (ANC) \>= 1500/mm\^3~* Platelet count \>= 100,000/mm\^3~* Bilirubin \< 2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3 times ULN)~* Alanine aminotransferase (ALT) \< 2.5 times ULN~* Serum creatinine =\< 1.5 mg/dL~* Serum albumin \>= 3.0 g/dL~* Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential; acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose~* Patients with history of previously treated malignancies who have no evidence of disease for last five years are allowed to participate~Exclusion Criteria:~* Patients who are pregnant or lactating~* Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =\< 3 weeks prior to cycle 1 day 1; mitomycin C or radio-immunotherapy 6 weeks prior to cycle 1 day 1~* Major surgery within four weeks before cycle 1 day 1~* Unstable cardiovascular function:~  * Symptomatic ischemia, or~ * Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular \[AV\] block or asymptomatic left anterior fascicular block \[LAFB\]/right bundle branch block \[RBBB\] will not be excluded), or~ * Congestive heart failure (CHF) of New York Heart Association (NYHA) class \>= 3, or~ * Myocardial infarction (MI) within 3 months of cycle 1 day 1 dose~* Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose~* Known to be HIV seropositive who are on anti-HIV drugs because of the unknown interactions between these drugs and the study agents~* Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA) or HBsAg (hepatitis B virus \[HBV\] surface antigen)~* Patients with active central nervous system (CNS) malignancy; asymptomatic small lesions are not considered active; treated lesions may be considered inactive if they are stable for at least 3 months~* Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea~* Grade \>= 2 peripheral neuropathy within 14 days prior to cycle 1 day 1~* History of seizures, movement disorders or cerebrovascular accident within the past 5 years prior to cycle 1 day 1~* Patients with muscular degeneration, uncontrolled glaucoma, or markedly decreased visual acuity based on physician's assessment~* Serious psychiatric or medical conditions that could interfere with treatment~* Participation in an investigational anti-cancer study within 3 weeks prior to cycle 1 day 1~* Concurrent therapy with approved or investigational anticancer therapeutic~* Presence of clinically significant ascites

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor) (Type: EXPERIMENTAL): Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
- Group II: Phase II Group I (gemcitabine, selinexor) (Type: EXPERIMENTAL): Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
- GroupIII: Phase II Group II (gemcitabine, selinexor) (Type: EXPERIMENTAL): Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).